Use of targeted exome sequencing in genetic diagnosis of Chinese familial hypercholesterolemia.
Familial hypercholesterolemia is an autosomal dominant inherited disease characterized by elevated plasma low-density lipoprotein cholesterol (LDL-C). It is mainly caused by mutations of the low-density lipoprotein receptor (LDLR) gene. Currently, the methods of whole genome sequencing or whole exome sequencing for screening mutations in familial hypercholesterolemia are not applicable in China due to high cost. We performed targeted exome sequencing of 167 genes implicated in the homozygous phenotype of a proband pedigree to identify candidate mutations, validated them in the family of the proband, studied the functions of the mutant protein, and followed up serum lipid levels after treatment. We discovered that exon 9 c.1268 T>C and exon 8 c.1129 T>G compound heterozygous mutations in the LDLR gene in the proband derived from the mother and father, respectively, in which the mutation of c.1129 T>G has not been reported previously. The mutant LDL-R protein had 57% and 52% binding and internalization functions, respectively, compared with that of the wild type. After 6 months of therapy, the LDL-C level of the proband decreased by more than 50% and the LDL-C of the other family members with heterozygous mutation also reduced to normal. Targeted exome sequencing is an effective method for screening mutation genes in familial hypercholesterolemia. The exon 8 and 9 mutations of the LDLR gene were pedigree mutations. The functions of the mutant LDL-R protein were decreased significantly compared with that of the wild type. Simvastatin plus ezetimibe was proven safe and effective in this preschool-age child.
Beijing Anzhen Hospital Affiliated with Capital Medical University, Beijing, China; Department of Atherosclerosis, Beijing Institute of Heart Lung and Blood Vessel Diseases, Beijing, China.
Wen-Feng
WF
Wu
Beijing Anzhen Hospital Affiliated with Capital Medical University, Beijing, China.
Li-Yuan
LY
Sun
Department of Atherosclerosis, Beijing Institute of Heart Lung and Blood Vessel Diseases, Beijing, China.
Xiao-Dong
XD
Pan
Beijing Anzhen Hospital Affiliated with Capital Medical University, Beijing, China; Department of Atherosclerosis, Beijing Institute of Heart Lung and Blood Vessel Diseases, Beijing, China.
Shi-Wei
SW
Yang
Department of Atherosclerosis, Beijing Institute of Heart Lung and Blood Vessel Diseases, Beijing, China.
Lv-Ya
LY
Wang
D000924:Anticholesteremic Agents / Q000627:therapeutic use; D044466:Asian People / Q000235:genetics; D001384:Azetidines / Q000627:therapeutic use; D002675:Child, Preschool; D002681:China; D004252:DNA Mutational Analysis / Q000379:methods*; D004359:Drug Therapy, Combination; D059472:Exome; D000069438:Ezetimibe; D005838:Genotype; D006801:Humans; D006937:Hypercholesterolemia / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics; D008297:Male; D009154:Mutation; D010375:Pedigree; D010641:Phenotype; D019821:Simvastatin / Q000627:therapeutic use; D016896:Treatment Outcome
D000924:Anticholesteremic Agents; D001384:Azetidines; D019821:Simvastatin; D000069438:Ezetimibe